生命科学资讯
生物技术与制药领域的最新动态
Langer-backed biotech looks to end cancer recurrence with surgical revolution
Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval
Seres to lay off 30% of employees, pause lead program in latest strategic shift
赛诺菲在经历“颠簸之旅”后解雇保罗·哈德森,挖角默克集团CEO执掌法国制药巨头。
Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
欧洲风投联手提振地区低迷的生物科技投资
European VCs join forces to boost flagging biotech investment in the region
更新:在莫德纳遭拒后,美国卫生与公众服务部支持FDA驳回mRNA流感疫苗申请的决定。
UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing
武田制药在整合计划中缩减波士顿业务规模。
Takeda downsizes Boston footprint amid consolidation effort
“唯有数据能拯救我们”:异体CAR-T生物技术公司在行业变革中争夺生存空间
‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on
上游公司公布Tezspire类似哮喘药物二期疗效,但未达最佳预期
Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario
Madrigal以44亿美元收购Ribo临床前siRNA项目,扩大Rezdiffra在MASH领域布局。
Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play
GE医疗推出新技术,助力医院远程维护床边心电图监测站。
GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations
Moderna遭FDA拒收信函针对mRNA流感疫苗,强烈反驳监管机构理由。
Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale
凯莱拉与恒瑞宣布肥胖症药物中期研究显示减重效果可达12%。
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
Evommune类似Dupixent的二期湿疹数据推动股价飙升75%
Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally
默克联手英国医疗科技公司,提升阴道治疗给药系统。
Merck teams up with British medtech to boost vaginal therapeutics delivery system
阿斯利康口服GLP-1药物二期试验成功,但暂未公布减重数据。
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
Nektar湿疹候选药物在长期二期数据中“满足所有条件”。
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
百时美施贵宝与Evinova签署全球开发合作协议
Bristol Myers and Evinova pen global development partnership
FDA拒绝批准Regenxbio公司亨特综合征基因疗法,CEO表示“担忧”。
FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'